Every material Form 8-K Alpha Cognition Inc. has filed with the SEC since April 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Alpha Cognition's board appointed director Robert Wills as non-executive Chair on June 16, 2026, filling the seat left by Len Mertz, who did not stand for re-election. At the same meeting, shareholders elected all six director nominees and ratified CBIZ CPAs P.C. as auditor, so the board's leadership change is limited to the chair role.
Robert Wills appointed non-executive Chair of the Board on June 16, 2026, succeeding the vacancy left by Len Mertz.
Shareholders set the board at six directors and elected all six nominees.
Robert Wills received 6,412,233 votes for and 23,606 withheld.
CBIZ CPAs P.C. ratified as auditor with 10,000,365 votes for and 533,188 against.
Alpha Cognition Inc. appointed Bethany Sensenig as a director on April 15, 2026. She previously served as CFO and Head of Operations at Radius Health, Inc. and holds a board seat at Supernus Pharmaceuticals and KalVista Pharmaceuticals; the filing describes no compensation beyond the company's standard non-employee director policy and grants.
Board appointment of Bethany Sensenig effective April 15, 2026
Initial grant of 5,489 restricted stock units and 6,991 stock options at an exercise price of $6.65 per share
Grants vest one year after the date of grant
Prior roles include CFO at Radius Health (May 2024 to April 2026) and CFO and Interim CEO at 9 Meters Biopharma
Alpha Cognition entered a settlement agreement dated April 10, 2026 with Galantos Pharma GmbH i.L., a company in liquidation, to extinguish future royalty and milestone payments under the Memogain Asset Purchase Agreement. In exchange for a one-time payment of EUR 5,214,220, Galantos agreed to release the company and its related parties from claims arising from the original agreement. The filing does not state the financial impact on the company's results.
One-time payment of EUR 5,214,220 to Galantos in full satisfaction of remaining contingent obligations, including royalty and milestone-related payments.
Galantos waives and releases the company and its related parties from causes of action arising from the Original Agreement.
Management states the settlement is an approximate 40% discount to the estimated market value of the remaining obligations, based on its own projections and comparable market benchmarks.
Agreement dated April 10, 2026; filed as Exhibit 10.1 to the report signed by CEO Michael McFadden on April 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Alpha Cognition Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →